Patrick Wingrove News Today

As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading...

(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations of $97.5 million. The Cambridge, Massachusetts-based company reaffirmed that it expects to receive approval from regulators for its ...

(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations of $97.5 million. The Cambridge, Massachusetts-based company reaffirmed that it expects to receive approval from regulat...

Sky-rocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the drugmaker's market value above $700 billion - surpassing both Tesla and Walmart. Lilly said its raised forecast reflects "greater clarity about the company's production expansion for the remainder of the year". In the short- to mid-term, the U.S. drugmaker expects sales growth for its weight-loss and diabetes treatments to primarily depend on how much it can produce and s...

Eli Lilly beat Wall Street estimates for first-quarter profit on Tuesday, helped by rising demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. The...

By Patrick Wingrove and Amina Niasse (Reuters) - Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June...

Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus vaccine Gardasil. The...

(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company's shares up more than 2% before the bell. Keytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward the end of the decade. The drug is seeing growth from use for additional...

Cigna plans to make close copies of AbbVies blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in...

By Patrick Wingrove and Amina Niasse (Reuters) - Cigna plans to make close copies of AbbVies blockbuster arthritis drug Humira available with no ...